Health Care Professionals Log In

Already Registered with Wyeth.com?

To view more information about PRISTIQ, please log in to your Wyeth.com account.

Log in or Register for Wyeth.com

Your registration gives you access to a wealth of information, including:

  • Educational Programs
  • Professional Resources
  • Wyeth Professional Tools – A.D.A.M. QuickSheets, 5-Minute Clinical Consult, Epocrates®, and more
Register with Wyeth.com
Pharmacokinetics

Pharmacokinetics

The metabolism of PRISTIQ is independent of the CYP2D6 pathway in the liver1

PRISTIQ demonstrated consistent pharmacokinetics regardless of CYP2D6 metabolizer status.1,2

Data from an open-label, 2-period, parallel-group, crossover study evaluating single doses of PRISTIQ 100 mg in healthy subjects who are extensive or poor CYP2D6 substrate metabolizers (N=14). The primary objective was to determine the difference in the pharmacokinetics of PRISTIQ when influenced by CYP2D6 polymorphism.2

  • ODV levels after administration of PRISTIQ were largely unaffected by genetic variability in CYP2D6 metabolism1
  • Metabolizer status can vary based on genetics or on other drugs that patients may be taking to treat comorbid conditions6
    • — On average, patients being treated for MDD may be on 3 additional medications prescribed to manage a variety of comorbid conditions2

Clinical Pharmacology of PRISTIQ1

Important Treatment Considerations

  • PRISTIQ must not be used concomitantly with an MAOI or within 14 days of stopping an MAOI. Allow 7 days after stopping PRISTIQ before starting an MAOI.
  • Development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome-like reactions have been reported with SNRIs and SSRIs alone, including PRISTIQ treatment, but particularly with concomitant use of serotonergic drugs, including triptans, with drugs that impair the metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. If concomitant use with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Concomitant use of PRISTIQ with serotonin precursors is not recommended.
  • SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may add to this risk.
Learn about Dosing and Administration of PRISTIQ
Next: Learning Center

244411-01